



Dnr. Oct. 12, 2022

Academic Cooperation
between
Karolinska Institutet at Department of Physiology & Pharmacology,
and
Viron Molecular Medicine Institute (MMI)

Viron Molecular Medicine Institute (MMI), Boston, MS, USA, and Karolinska Institutet at Department of Physiology and Pharmacology, Sweden believe that:

1. Mutual benefit can be derived from academic exchange, cultural interchange and cooperation in teaching and research;
2. The parties regard the following areas of cooperation as desirable and feasible within the limits of available resources and interests:
 - (i) Exchange of doctoral students and academic staff members;
 - (ii) Collaborative research and possible exchange of academic papers;
 - (iii) Organization of joint academic and scientific activities, such as courses, conferences, seminars, workshops or lectures
 - (iv) Exchange of scientific materials, publications and other information;
 - (v) Co-operation in training projects for specified areas of development;
 - (vi) Opportunities for other forms of co-operation, such as the delivery of award and non-award courses.
3. The terms of specific areas of cooperation shall be further considered and agreed upon in writing by the parties prior to the initiation of any particular programme or activity.
4. This Agreement describes in general terms the basis upon which the Parties intend to collaborate. All activities undertaken pursuant to the Agreement are subject to the approval of the Parties themselves. This Agreement does not affect the ability of the Parties to enter into other agreements or arrangements. Any specific programme or activity will be subject to mutual consent, availability of funds and approval of both Parties.
5. Each party shall ensure that its activities under the cooperation fully comply with all recognized international laws, regulations, guidelines and recommendations in relevant fields, that are in force during the term of this agreement, including but not limited to:
 - (i) Any UNESCO Declaration on Ethics Issues, for instance the Universal Declaration on the Human Genome and Human Rights, the International Declaration on Human Genetic Data and the Universal Declaration on Bioethics and Human Rights;

- (ii) Generally accepted principles of academic freedom and in particular the Recommendation concerning the Status of Higher Education Teaching Personnel, adopted by the UNESCO General Conference in 1997;
- (iii) All applicable local, government laws and regulations and guidelines governing health and safety, data protection, and where relevant, the use of human or animal subjects, good laboratory practice and good clinical practice; and
- (iv) Any World Medical Association policy included in the Handbook of WMA Policy, for instance The Helsinki Declaration on Ethical Principles for Medical Research involving Human Subjects, International Code of Medical Ethics, Declaration of Taipei on Ethical Considerations regarding Health Databases and Biobanks and Statement on Animal Use in Biomedical Research;

The Parties acknowledge that in all research activities under the collaboration they shall secure all necessary approvals from the relevant research ethics committees before undertaking any part of a research project requiring ethics committee approval. Each Party shall also obtain properly signed consent and acknowledgement forms from any human subjects or their legal guardians to be involved in the project;

The Parties will cooperate for the purpose of ensuring that each of them complies with ethical obligations and will therefore share information relating to ethical approvals obtained in a transparent manner;

The Parties agree to ensure that all teaching and research personnel engaged in the collaboration under the current Agreement shall be entitled to full academic freedom as referred to in (ii) above.

6. The parties agree that this Agreement does not give rise to any legal relationship, rights, duties or consequences, except the obligation in clause 5 above. Specifically neither Party acquires any license under intellectual property rights of the other Party.
7. Neither Party shall use the trade/official-marks or trade/official names, of the other or of any of its affiliates, directly or indirectly, in connection with any product, promotion, advertising, press releases, service or publication without the prior written consent of the other Party.
8. This Agreement will be effective when signed by both parties. The term of duration of this Agreement shall be of five (5) years and may be extended for additional five-year periods by written consent of the parties. Either party may terminate this Agreement by giving the other party at least six (6) months written notice.

For this purpose, the responsible signing parties will be the Head of the Department of Physiology and Pharmacology and the President at Karolinska Institutet and the Chief Operating Officer and the President & Director of Viron Molecular Medicine Institute

Daniel A. Walz

.....
Daniel A. Walz, Ph.D.
Title: Chief Operating Officer
Viron Molecular Medicine Institute
One Boston Place, Boston, MA, USA

Date: Oct. 12, 2022

Bhanu P. Jena

.....
Prof. Bhanu P. Jena
President & Director

Sph

.....
Sophie Erhardt, Ph.D.
Head of Department
Department of Physiology and Pharmacology
Karolinska Institutet, Stockholm, Sweden

Date: Oct 25, 2022

Ole Petter Ottersen

.....
Prof Ole Petter Ottersen
President

Viron Molecular Medicine Institute

Karolinska Institutet

Date: October 12, 2022

Date:

Contact persons and contact details:

Viron Molecular Medicine Institute

**Department of Physiology and
Pharmacology
Karolinska Institutet**

Heather Collins

Title: Executive Assistant

Postal address: One Boston Place, 26th Floor

Visting address: One Boston Place, 26th

Floor, Boston, MA, 02108, USA

Tel: 781-956-9799/617-283-1087

E-mail: contact@vironinstitute.org

Web: vironinstitute.com

Christina Johansson

Head Administration

Biomedicum

Solnavägen 9, Stockholm

Tel: +468 5248 xx xx

E-mail: christina.johansson@ki.se

Web: ki.se

